Panbela Therapeutics Inc (PBLA) Down 1.64% in Premarket Trading

Panbela Therapeutics Inc (PBLA) has fallen Tuesday morning, with the stock declining -1.64% in pre-market trading to 1.2. PBLA's short-term technical score of 6 indicates that the stock has traded less bullishly over the last month than 94% of stocks on the market. In the Biotechnology industry, which ranks 90 out of 146 industries, PBLA ranks higher than 9% of stocks. Panbela Therapeutics Inc has risen 4.27% over the past month, closing at $1.20 on February 6. During this period of time, the stock fell as low as $1.11 and as high as $1.50. PBLA has an average analyst recommendation of Strong Buy. The company has an average price target of $172.50.

PBLA has an Overall Score of 32. Find out what this means to you and get the rest of the rankings on PBLA!

See Full PBLA Report

Panbela Therapeutics Inc has a Long-Term Technical rank of 9. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 91% of the market scoring higher. In the Biotechnology industry which is number 46 by this metric, PBLA ranks better than 46% of stocks.

Important Dates for Investors in PBLA:

-Panbela Therapeutics Inc is set to release earnings on 2024-03-21. Over the last 12 months, the company has reported EPS of $-157.02. -We do not have a set dividend date for Panbela Therapeutics Inc at this time. Click Here To Get The Full Report on Panbela Therapeutics Inc (PBLA)